Merck KGaA ADR
MKKGY: PINX (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $67.00 | Vsnvg | Fhlmnxck |
Merck KGaA's Benefiting From Solid Organic Growth and FX Benefits
/s3.amazonaws.com/arc-authors/morningstar/27df33e4-c5eb-4dc8-805e-babc7c688b65.jpg)
Business Strategy and Outlook
Merck KGaA has made a series of acquisitions and divestitures in the past decade or so to position the group for solid long-term growth in three key segments: life sciences, performance materials, and healthcare. However, after robust results in 2020 and 2021 due to COVID-19-related benefits particularly in its life sciences business, we think the company's intermediate-term growth may soften toward more historic norms.